Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
-
Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary)
;
Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ;
Escudier, Bernard (Gustave Roussy) ;
Pal, Sumanta (City of Hope National Medical Center) ;
Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ;
Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ;
Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ;
Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ;
Park, Se Hoon (Samsung Medical Center) ;
Geertsen, Poul F. (Copenhagen University Hospital) ;
Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Markby, David W. (Exelixis, Inc) ;
Arroyo, Alan (Exelixis, Inc) ;
Dean, Mark (Exelixis, Inc) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
George, Daniel (Duke University Medical Center) ;
Universitat Autònoma de Barcelona